POMDOCTOR Ltd
No SEC Form 4 filings for $POM in the last 30 days.
See all $POM insider activity →POMDOCTOR LIMITED (Nasdaq: POM) received a delisting notice from Nasdaq due to its ADS price falling below $1.00 for 30 consecutive days. The company is ineligible for a compliance period due to a recent reverse stock split. POM plans to appeal the decision by October 13, 2026, to avoid suspension and delisting.
Pomdoctor Limited reported a GAAP EPS of -$1.46 and revenue of $27.26M for the first half of 2026, up 4.8% year-over-year. The company had RMB12.6 million (US$1.9 million) in cash and cash equivalents as of June 30, 2026. The stock price increased by 1.03%.
POMDOCTOR LIMITED (NASDAQ: POM) said it is upgrading its online chronic-disease platform to position itself as infrastructure for predictive healthcare data and services. The plan integrates wearables, AI analytics, physician services, real-world healthcare data, and payment networks, aiming to shift care from reactive treatment to proactive monitoring and long-term management.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning POM (POMDOCTOR Ltd). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent POM coverage spans financial news, corporate actions and earnings.
Potential suspension and delisting pressure on POM stock.
Negative earnings and modest revenue growth likely weigh on the stock.
The PR signals a strategic pivot toward an AI/wearables/data-and-payments ecosystem, but provides no measurable financial targets or near-term milestones.
The appointment of Luo Guoji as director and VP signals potential strategic shifts or increased insider influence, which may positively influence investor confidence.
Shareholder legal deadlines are unlikely to influence POM's stock in the near term.
AlphAI scores every news story that mentions POM with an AI model for sentiment and relevance, and aggregates insider trades from POMDOCTOR Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
POMDOCTOR LIMITED (Nasdaq: POM) received a delisting notice from Nasdaq due to its ADS price falling below $1.00 for 30 consecutive days. The company is ineligible for a compliance period due to a recent reverse stock split. POM plans to appeal the decision by October 13, 2026, to avoid suspension and delisting.
2 min readPomdoctor Limited reported a GAAP EPS of -$1.46 and revenue of $27.26M for the first half of 2026, up 4.8% year-over-year. The company had RMB12.6 million (US$1.9 million) in cash and cash equivalents as of June 30, 2026. The stock price increased by 1.03%.
1 min readPOMDOCTOR LIMITED (NASDAQ: POM) said it is upgrading its online chronic-disease platform to position itself as infrastructure for predictive healthcare data and services. The plan integrates wearables, AI analytics, physician services, real-world healthcare data, and payment networks, aiming to shift care from reactive treatment to proactive monitoring and long-term management.
3 min readPOMDOCTOR Ltd (POM) has filed an initial insider ownership report (Form 3) for Luo Guoji, identifying him as both a director and Vice President of the company. The filing, dated March 31, 2026, indicates his new insider status but reports no transactions in POMDOCTOR Ltd securities. This establishes Luo Guoji's reporting requirements for future beneficial ownership changes.
2 min readHolzer & Holzer, LLC is reminding investors of the April 6, 2026, lead plaintiff deadlines for several shareholder class action lawsuits. These lawsuits are filed against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE). The firm encourages investors who suffered significant losses during the specified periods to contact them to discuss their legal rights.
1 min readThe Rosen Law Firm is encouraging investors of PomDoctor Ltd. (NASDAQ: POM) to secure legal counsel by the April 7, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme, with insiders using offshore accounts to dump shares during a price inflation campaign. The firm, known for its success in securities class actions, is offering representation on a contingency fee basis.
2 min read
